Navigation Links
Right warfarin dose determined by 3 genes
Date:3/20/2009

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are published in the scientific journal PLoS Genetics.

"We have previously studied selected genes that can affect warfarin treatment. Now that we have gone in and scanned the entire genome, we see that the two most important genes are among those we previously singled out," says Mia Wadelius, a researcher at Uppsala University, and one of the scientists behind the study.

She also says that this is the first truly large warfarin study in which all genes were reviewed at the same time. More than 1,000 warfarin patients and roughly 370,000 gene variants, covering the entire human genome, were studied.

"The adequate warfarin dosage for a patient is determined by three genes: VKORC1, CYP2C9, and CYP4F2. This is a step forward for a large group of patients, because it will be easier to determine the dosage, and the treatment will be less risky," says Mia Wadelius.

Patients vary in their sensitivity to warfarin, which makes treatment initially a risky balancing act between bleeding and blood clots. Mia Wadelius says that the variation is great among patients, sometimes up to a difference of twenty times. But now that researchers have managed to identify which genes underlie this variation, it will be possible to predict different patients' needs for warfarin more precisely, rendering treatment safer. The next step is to look for markers for bleeding.

"We will continue to look for genetic variants that influence the risk of bleeding, which can be a reaction to warfarin treatment, though a rare one. The findings of the Swedish study will be combined with those from a British study in order to attain a sufficiently robust analysis of risks of bleeding," says Mia Wadelius.


'/>"/>

Contact: Mia Wadelius
mia.wadelius@medsci.uu.se
46-018-611-4945
Uppsala University
Source:Eurekalert

Page: 1

Related medicine news :

1. Stressed-Out Moms Carry Babies on the Right
2. Bright tumors, dim prospects
3. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
4. Right breakfast bread keeps blood sugar in check all day
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Experts Agree. Ohios Technology Investment Future Looks Bright
7. L.A. Playwright Creates an Enormous Wave with His New Book, Touch the Ocean
8. Civil Rights and Medical Leaders Call for Social Justice in Health Care
9. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
10. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
11. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... ability of physical therapist assistants, under direct supervision of a licensed physical therapist, ... physical therapy receives a consultation and treatment plan from a licensed physical therapist ...
(Date:12/5/2016)... CHICAGO, IL (PRWEB) , ... December 05, 2016 , ... ... value to the individual looking to buy neoprene knee sleeves for lifting ... activity. The design focuses heavily on two main aspects to provide a higher quality ...
(Date:12/5/2016)... (PRWEB) , ... December 05, ... ... professional calibrations is an excellent way to ensure moisture measurements are consistently ... time-consuming and impractical. , Now, METTLER TOLEDO offers a solution: ...
(Date:12/5/2016)... ... 05, 2016 , ... Z-Medica, LLC, a leading developer and ... American College of Surgeons (ACS) to provide basic bleeding control instructor training to ... course is a pilot program that fulfills the intent of the White House’s ...
(Date:12/4/2016)... , ... December 02, 2016 , ... ... give patients better access to nutraceuticals and help doctors more efficiently manage their ... portal and practice management software platform for Integrative and Functional Medicine. , ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016 The global  non-invasive prenatal testing market  is ... report by Grand View Research, Inc. Evolution of prenatal testing in the ... serum screening and invasive diagnostic testing to determine the likelihood of fetal ... the forecast period. Continue Reading ... ...
(Date:12/4/2016)... Blueprint Medicines Corporation (NASDAQ: BPMC ... kinase medicines for patients with genomically defined diseases, ... trial evaluating BLU-285, an investigational medicine for the ... Blueprint Medicines is developing BLU-285 as a potent, ... 90 to 95 percent of patients with SM ...
(Date:12/4/2016)... , Dec. 2, 2016  Former Attorney General of ... , a partner at the law firm of Kahn Swick ... investigation into Lannett Company, Inc. (NYSE: LCI ). ... published an article titled "U.S. Charges in Generic-Drug Probe to ... by the Justice Department, begun about two years ago, now ...
Breaking Medicine Technology: